In a significant advancement for breast cancer treatment, the U.S. Food and Drug Administration (FDA) has recently approved ribociclib, marketed as Kisqali, in conjunction with endocrine therapy as an adjuvant treatment for early-stage high-risk breast cancer. Previously, this medication was indicated solely for metastatic settings; however, recent strides have allowed for its application in early-stage
Health
Bladder cancer, particularly muscle-invasive bladder cancer (MIBC), poses significant challenges in terms of treatment effectiveness and patient survival. The recent findings from the NIAGARA trial mark a pivotal moment in oncological therapy, presenting compelling evidence for the benefits of combining immune checkpoint inhibitors with conventional chemotherapy. This article delves into the trial’s findings, implications for
The landscape of cancer therapy is constantly evolving. Recent clinical trials have uncovered promising treatments as researchers grapple with diseases that have long been overlooked, particularly within the realm of rare cancers. Advanced squamous cell carcinoma of the anal canal (SCAC) represents one such challenge, characterized by its increasing incidence and significant unmet medical need.
The transition into menopause is a significant physiological event that brings along a series of changes within a woman’s body, particularly concerning hormonal fluctuations. As estrogen and progesterone levels drop, women may face an array of symptoms, including hot flashes, mood changes, and alterations in metabolism. A recent systematic review and meta-analysis have shed light
The intersection of healthcare policy and political agendas has become a contentious battleground in recent times, particularly highlighted by Former President Donald Trump’s promise to provide free in vitro fertilization (IVF) treatments. This pledge has incited backlash from several factions within the Republican Party, raising questions about the party’s direction and core beliefs regarding government
A recent phase III trial has revealed that the inexpensive antidepressant, mirtazapine, is no more effective than a placebo in alleviating severe, persisting breathlessness caused by chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD). The study, led by Irene Higginson, BMBS, PhD, from Kings College London, found that after 56 days of treatment,
The recent revelations about the inefficiencies and malpractices within the U.S. organ transplant system have sent shockwaves throughout the community. Stories of presumed deceased organ donors waking up and panicking, whispering “Help me,” or the threat of being “cremated alive” by organ transplant executives are enough to induce nightmares. The shortcomings exposed during the House
CAR T-cell therapy has become a promising treatment option for patients with cancer, showing potential for long-term remission and even cure. However, recent reports have raised concerns about the risk of second primary malignancies (SPM) associated with this therapy. A systematic literature review and meta-analysis aimed to shed light on this issue and compare the
The phase IIIa SCALE Kids trial conducted by Claudia Fox, MD, of the University of Minnesota Medical School, explored the impact of liraglutide (Saxenda) on young children with obesity. It was found that when liraglutide was added to lifestyle intervention, there was a significant reduction in BMI among children aged 6 to less than 12
In a recent analysis of two phase III trials, researchers found significant benefits in using perioperative nivolumab in post-surgical non-small cell lung cancer (NSCLC) patients. The study compared the outcomes of patients who received neoadjuvant nivolumab and chemotherapy versus those who also received adjuvant nivolumab after surgery. The results showed a 40% reduction in the